GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Avricore Health Inc (OTCPK:AVCRF) » Definitions » Price-to-Operating-Cash-Flow

Avricore Health (Avricore Health) Price-to-Operating-Cash-Flow : 37.28 (As of May. 30, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Avricore Health Price-to-Operating-Cash-Flow?

As of today (2024-05-30), Avricore Health's share price is $0.11185. Avricore Health's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Hence, Avricore Health's Price-to-Operating-Cash-Flow Ratio for today is 37.28.

The historical rank and industry rank for Avricore Health's Price-to-Operating-Cash-Flow or its related term are showing as below:

AVCRF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 31.25   Med: 38.75   Max: 92.5
Current: 38.75

During the past 13 years, Avricore Health's highest Price-to-Operating-Cash-Flow Ratio was 92.50. The lowest was 31.25. And the median was 38.75.

AVCRF's Price-to-Operating-Cash-Flow is ranked worse than
79.28% of 111 companies
in the Medical Diagnostics & Research industry
Industry Median: 17.21 vs AVCRF: 38.75

Avricore Health's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $0.00. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

During the past 13 years, Avricore Health's highest 3-Year average Operating Cash Flow per Share Growth Rate was 77.80% per year. The lowest was -113.20% per year. And the median was 22.65% per year.


Avricore Health Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Avricore Health's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avricore Health Price-to-Operating-Cash-Flow Chart

Avricore Health Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 24.29

Avricore Health Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 95.00 24.29

Competitive Comparison of Avricore Health's Price-to-Operating-Cash-Flow

For the Diagnostics & Research subindustry, Avricore Health's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avricore Health's Price-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Avricore Health's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Avricore Health's Price-to-Operating-Cash-Flow falls into.



Avricore Health Price-to-Operating-Cash-Flow Calculation

Avricore Health's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=0.11185/0.003
=37.28

Avricore Health's Share Price of today is $0.11185.
Avricore Health's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Avricore Health Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Avricore Health's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Avricore Health (Avricore Health) Business Description

Traded in Other Exchanges
Address
1120 - 789 West Pender Street, Vancouver, BC, CAN, V6C 1H2
Avricore Health Inc is a Canada based company. The company is involved in the business of health data and point-of-care technologies. The Company has only one segment, being the HealthTab - Point of Care Business in Canada. The Company's revenues are generated from operating leases of the POCT system and sale of testing panels.

Avricore Health (Avricore Health) Headlines

From GuruFocus

Avricore Health Announces Lifting of Management Cease Trade Order

By Marketwired Marketwired 06-04-2019

Avricore Health Extends Closing of Placement

By GlobeNewswire GlobeNewswire 07-20-2019

Avricore Health Amends Options

By GlobeNewswire GlobeNewswire 09-11-2020

VANC Pharmaceuticals Inc. Provides Corporate Update

By GlobeNewswire GlobeNewswire 11-02-2018

VANC Announces Agreement for Acquisition of Corozon Platform

By GlobeNewswire GlobeNewswire 04-12-2018